Drug Eruptions

"Drug Eruptions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.

Descriptor ID	D003875
MeSH Number(s)	C17.800.174.600 C20.543.206.380 C25.100.468.380
Concept/Terms	Drug Eruptions Drug Eruptions Drug Eruption Eruption, Drug Eruptions, Drug Dermatitis Medicamentosa Dermatitis, Adverse Drug Reaction Morbilliform Drug Reaction Morbilliform Drug Reaction Drug Reaction, Morbilliform Drug Reactions, Morbilliform Morbilliform Drug Reactions Reaction, Morbilliform Drug Reactions, Morbilliform Drug Maculopapular Exanthem Exanthem, Maculopapular Exanthems, Maculopapular Maculopapular Exanthems Morbilliform Exanthem Exanthem, Morbilliform Exanthems, Morbilliform Morbilliform Exanthems Maculopapular Drug Eruption Drug Eruption, Maculopapular Drug Eruptions, Maculopapular Eruption, Maculopapular Drug Eruptions, Maculopapular Drug Maculopapular Drug Eruptions

Below are MeSH descriptors whose meaning is more general than "Drug Eruptions".

Diseases [C]
Skin and Connective Tissue Diseases [C17]
Skin Diseases [C17.800]
Dermatitis [C17.800.174]
Drug Eruptions [C17.800.174.600]
Immune System Diseases [C20]
Hypersensitivity [C20.543]
Drug Hypersensitivity [C20.543.206]
Drug Eruptions [C20.543.206.380]
Chemically-Induced Disorders [C25]
Drug-Related Side Effects and Adverse Reactions [C25.100]
Drug Hypersensitivity [C25.100.468]
Drug Eruptions [C25.100.468.380]

Below are MeSH descriptors whose meaning is related to "Drug Eruptions".

Below are MeSH descriptors whose meaning is more specific than "Drug Eruptions".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Eruptions" by people in this website by year, and whether "Drug Eruptions" was a major or minor topic of these publications.

Bar chart showing 87 publications over 27 distinct years, with a maximum of 11 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	1	0	1
1994	0	1	1
1996	1	1	2
1997	1	0	1
1998	1	1	2
1999	0	3	3
2001	0	1	1
2002	1	1	2
2003	2	1	3
2004	2	0	2
2005	2	1	3
2006	0	1	1
2007	1	1	2
2008	0	1	1
2009	3	0	3
2010	1	2	3
2011	0	1	1
2012	5	1	6
2013	3	5	8
2014	0	1	1
2015	1	3	4
2016	5	2	7
2017	6	5	11
2018	6	1	7
2019	3	2	5
2020	2	1	3
2021	3	0	3

Below are the most recent publications written about "Drug Eruptions" by people in Profiles.

Bloomquist MS, Curry JL, Krishnan B, Rivero G, Curry CV, Diwan AH. Ibrutinib skin toxicities: Report of two cases. J Cutan Pathol. 2022 Apr; 49(4):363-368.

View in: PubMed
Seervai RNH, Cho WC, Chu EY, Marques-Piubelli ML, Ledesma DA, Richards K, Heberton MM, Nelson KC, Nagarajan P, Torres-Cabala CA, Prieto VG, Curry JL. Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. J Cutan Pathol. 2022 Jan; 49(1):61-81.

View in: PubMed
Wu J, Liu D, Offin M, Lezcano C, Torrisi JM, Brownstein S, Hyman DM, Gounder MM, Abida W, Drilon A, Harding JJ, Sullivan RJ, Janku F, Welsch D, Varterasian M, Groover A, Li BT, Lacouture ME. Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. Invest New Drugs. 2021 06; 39(3):785-795.

View in: PubMed
Choi J, Anderson R, Blidner A, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL, Lacouture ME. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Support Care Cancer. 2020 Dec; 28(12):6119-6128.

View in: PubMed
Marques-Piubelli ML, Tetzlaff MT, Nagarajan P, Duke TC, Glitza Oliva IC, Ledesma DA, Aung PP, Torres-Cabala CA, Wistuba II, Prieto VG, Nelson KC, Curry JL. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. J Cutan Pathol. 2020 Oct; 47(10):954-959.

View in: PubMed
Jenkinson HA, Aung PP, Huen A. Mycosis fungoides manifesting as a morbilliform eruption mimicking a viral exanthem. Cutis. 2020 Jun; 105(6):E27-E29.

View in: PubMed
Gordon SW, McGuire WP, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic AS. Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. Am J Clin Oncol. 2019 08; 42(8):649-654.

View in: PubMed
Jordan MB, Allen CE, Greenberg J, Henry M, Hermiston ML, Kumar A, Hines M, Eckstein O, Ladisch S, Nichols KE, Rodriguez-Galindo C, Wistinghausen B, McClain KL. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 11; 66(11):e27929.

View in: PubMed
Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019 Nov; 46(11):872-877.

View in: PubMed
Doan HQ, Hu MI, Goldstein J, Piha-Paul SA, Subbiah V, Patel AB. Vandetanib photoinduced cutaneous toxicities. Cutis. 2019 May; 103(5):E24-E29.

View in: PubMed

People

Explore

Similar Concepts

Top Journals